Does Rallies show Form 4 insider transactions for NUVB?

Yes. Rallies tracks NUVB insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is NUVB research on Rallies investment advice?

No. Rallies provides research, data, and educational context for NUVB. It does not provide personalized investment advice.

NUVB (Nuvation Bio Inc.) Stock Analysis - Insider Trades

Nuvation Bio Inc. (NUVB) is a publicly traded Healthcare sector company. As of May 20, 2026, NUVB trades at $4.45 with a market cap of $1.47B and a P/E ratio of -10.73. NUVB moved +6.49% today. Year to date, NUVB is -47.50%; over the trailing twelve months it is +107.83%. Its 52-week range spans $1.54 to $9.75. Analyst consensus is strong buy with an average price target of $13.17. Rallies surfaces NUVB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading NUVB stock inside the company?

Recent NUVB insider activity includes Wentworth Kerry sold 36.75K, Liu Dongfang sold 50.00K, Wentworth Kerry sold 200.00K, Liu Dongfang sold 150.00K, and Liu Dongfang sold 10.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

NUVB Key Metrics

Key financial metrics for NUVB
Metric	Value
Price	$4.45
Market Cap	$1.47B
P/E Ratio	-10.73
EPS	$-0.42
Dividend Yield	0.00%
52-Week High	$9.75
52-Week Low	$1.54
Volume	4.47M
Avg Volume	0
Revenue (TTM)	$143.05M
Net Income	$-145.99M
Gross Margin	0.00%

Recent NUVB Insider Trades

Wentworth Kerry sold 36.75K (~$184.28K) on Apr 17, 2026.
Liu Dongfang sold 50.00K (~$251.00K) on Apr 17, 2026.
Wentworth Kerry sold 200.00K (~$903.56K) on Apr 6, 2026.
Liu Dongfang sold 150.00K (~$1.17M) on Dec 1, 2025.
Liu Dongfang sold 10.00K (~$80.00K) on Nov 26, 2025.

Latest NUVB News

Nuvation Bio Completes Thermo Fisher Tech Transfer for IBTROZI Manufacturing — May 13, 2026
Nuvation Bio Logs $18.5M Q1 IBTROZI Revenues, Secures Japan Rights for Safusidenib — May 4, 2026
Analysts Raise Nuvation Bio 2026 Revenue Forecast 15.6%, Q1 Seen at $62.3M — May 1, 2026
Nuvation Bio’s Taletrectinib Recommended in NCCN CNS Guidelines with 76.5% Intracranial Response — Apr 27, 2026
IBTROZI Shows 49.7-Month Duration and 89.8% Response in ROS1+ NSCLC Trials — Apr 21, 2026

NUVB Analyst Consensus

7 analysts cover NUVB: 0 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $13.17.

Common questions about NUVB

Who is trading NUVB stock inside the company?: Recent NUVB insider activity includes Wentworth Kerry sold 36.75K, Liu Dongfang sold 50.00K, Wentworth Kerry sold 200.00K, Liu Dongfang sold 150.00K, and Liu Dongfang sold 10.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for NUVB?: Yes. Rallies tracks NUVB insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is NUVB research on Rallies investment advice?: No. Rallies provides research, data, and educational context for NUVB. It does not provide personalized investment advice.